pioglitazone has been researched along with Adenocarcinoma of Lung in 1 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Adenocarcinoma of Lung: A carcinoma originating in the lung and the most common lung cancer type in never-smokers. Malignant cells exhibit distinct features such as glandular epithelial, or tubular morphology. Mutations in KRAS, EGFR, BRAF, and ERBB2 genes are associated with this cancer.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In our work we investigate the anti-tumor effects of pioglitazone in in vitro models of non small cell lung cancer (NSCLC) and also, we generated ex-vivo three-dimensional (3D) cultures from human lung adenocarcinoma (ADK) as a model to test drug efficacy observed in vitro." | 3.91 | Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC. ( Barra, G; Ciaramella, V; Ciardiello, F; Corte, CMD; De Vita, F; Di Liello, R; Esposito, G; Martinelli, E; Morgillo, F; Orditura, M; Sasso, FC; Sparano, F; Troiani, T; Viscardi, G, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ciaramella, V | 1 |
| Sasso, FC | 1 |
| Di Liello, R | 1 |
| Corte, CMD | 1 |
| Barra, G | 1 |
| Viscardi, G | 1 |
| Esposito, G | 1 |
| Sparano, F | 1 |
| Troiani, T | 1 |
| Martinelli, E | 1 |
| Orditura, M | 1 |
| De Vita, F | 1 |
| Ciardiello, F | 1 |
| Morgillo, F | 1 |
1 other study available for pioglitazone and Adenocarcinoma of Lung
| Article | Year |
|---|---|
Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC.
Topics: A549 Cells; Adenocarcinoma of Lung; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell P | 2019 |